化学信息：
| 化学名 | 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide |
|
| 简称 | Vilazodone | |
| 别名 |
EMD 68843, SB 659746A, EMD-68843, EMD68843, SB-659746A, SB659746A |
|
| 中文名 | 维拉佐酮 | |
| 化学式 | C26H27N5O2 | |
| 分子量 | 441.52 | |
| CAS号 | 163521-12-8 | |
| 纯度 | 98% | |
| 溶剂/溶解度 |
Water<1mg/ml; DMSO5mg/ml; Ethanol<1mg/ml |
|
| 溶液配制 | 5mg加入1.13ml DMSO，或者每4.42mg加入1ml DMSO，配制成10mM溶液。SD2452-10mM用DMSO配制。 |
生物信息：
| 产品描述 | Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression. | ||||
| 信号通路 | GPCR & G Protein; Neuronal Signaling | ||||
| 靶点 | SSRI | 5-HT1A | － | － | － |
| IC50 | － | － | － | － | － |
| 体外研究 | Vilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment. | ||||
| 体内研究 | N/A | ||||
| 临床实验 | N/A | ||||
| 特征 | N/A | ||||
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
| 酶活性检测实验 | |
| 方法 | N/A |
| 细胞实验 | |
| 细胞系 | N/A |
| 浓度 | N/A |
| 处理时间 | N/A |
| 方法 | N/A |
| 动物实验 | |
| 动物模型 | N/A |
| 配制 | N/A |
| 剂量 | N/A |
| 给药方式 | N/A |
| 产品编号 | 产品名称 | 包装 |
| SD2452-10mM | Vilazodone (SSRI抑制剂) | 10mM×0.2ml |
| SD2452-5mg | Vilazodone (SSRI抑制剂) | 5mg |
| SD2452-25mg | Vilazodone (SSRI抑制剂) | 25mg |
| — | 说明书 | 1份 |
保存条件：
-20℃保存，至少一年有效。5mg和25mg包装也可室温保存，至少6个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
